Neurogene Inc. (NASDAQ:NGNE) Receives $42.50 Average Price Target from Analysts

Neurogene Inc. (NASDAQ:NGNE) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $42.50.

NGNE has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Wednesday, October 8th. Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, HC Wainwright upped their price target on shares of Neurogene from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP grew its holdings in shares of Neurogene by 120.4% during the 1st quarter. Baker BROS. Advisors LP now owns 1,486,200 shares of the company’s stock worth $17,403,000 after purchasing an additional 811,750 shares during the period. Balyasny Asset Management L.P. purchased a new position in Neurogene in the 3rd quarter valued at approximately $12,114,000. ArrowMark Colorado Holdings LLC raised its position in Neurogene by 1.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock valued at $10,326,000 after purchasing an additional 10,442 shares in the last quarter. Jennison Associates LLC raised its holdings in Neurogene by 55.0% in the second quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock valued at $2,505,000 after acquiring an additional 59,479 shares in the last quarter. Finally, Blair William & Co. IL lifted its position in shares of Neurogene by 6.4% during the 3rd quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock worth $2,458,000 after purchasing an additional 8,584 shares during the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $20.01 on Thursday. The company has a market cap of $309.95 million, a P/E ratio of -4.87 and a beta of 1.62. Neurogene has a 52-week low of $6.88 and a 52-week high of $37.27. The firm’s fifty day moving average is $24.27 and its two-hundred day moving average is $22.01.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.27. As a group, analysts forecast that Neurogene will post -4.27 EPS for the current fiscal year.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.